Matsubara, Yuki
Toriyama, Kazuhiro
Kadowaki, Shigenori http://orcid.org/0000-0001-9923-5309
Ogata, Takatsugu
Nakazawa, Taiko
Kato, Kyoko
Nozawa, Kazuki
Narita, Yukiya
Honda, Kazunori
Masuishi, Toshiki
Bando, Hideaki
Ando, Masashi
Tajika, Masahiro
Oze, Isao
Hosoda, Waki
Muro, Kei
Article History
Received: 23 April 2022
Accepted: 10 December 2022
First Online: 3 January 2023
Declarations
:
: The institutional review board of Aichi Cancer Center Hospital, Japan, approved this study (R021076). The institutional review board also waived the requirement for informed consent because of the observational retrospective nature of this study, with an opt-out option indicated at the institution’s website.
: YM received an honorarium from Takeda, Merck BioPharma, and Taiho. SK received an honorarium from Eli Lilly, Taiho, Ono, Bristol-Myers Squibb, Chugai, Bayer, Merck Serono, Daiichi Sankyo, and Esai as well as research funding from Taiho, Eli Lilly, MSD, Chugai, Nobelpharma, Ono, Daiichi Sankyo, and Yansen. TO received an honorarium from Ono, Bristol-Myers Squibb, Taiho, MSD, and Eli Lilly. TN received an honorarium from Eli Lilly. YN received an honorarium from Yakult Honsha, Taiho, Eli Lilly, Daiichi Sankyo, and AstraZeneca as well as research funding from Ono and Bristol-Myers Squibb. YN is also a member of the advisory board of Daiichi Sankyo. TM received an honorarium from Takeda, Chudai, Merck BioPharma, Taiho, Bayer, Eli Lilly, Yakult Honsha, Sanofi, Daiichi Sankyo, Ono, and Bristol-Myers Squibb as well as research funding from MSD, Daiichi Sankyo, Ono, and Novartis. HB received an honorarium from Ono, Eli Lilly, and Taiho as well as research funding from Ono. MT received an honorarium from EA Pharma, Otsuka Pharmaceutical Factory, and Bristol-Myers Squibb. KM received an honorarium from Ono, Chugai, Takeda, Taiho, Sanofi, Bristol-Myers Squibb, Eli Lilly, and Bayer; research funding from Solasia Pharma, Merck Serono, Daiichi Sankyo, Parexel International, Pfizer, MSD, Amgen, ONO, Astellas, Sanofi, Taiho, and Esai; and consulting fees from AstraZeneca, Ono, and Amgen. KM is also a member of the advisory boards of Ono, MSD, AstraZeneca, Daiichi Sankyo, and Solasia Pharma.
: All data and materials used for this study are available on request.